# US 2004/0082572 A1 · Benzodiazepine derivatives as app modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082572 A1
- Document ID: US20040082572A1
- Status: Published application
- Kind: A1
- Application number: 10/296,428
- Filed: 2002-11-22
- Published: 2004-04-29
- Earliest claimed: 2000-05-24
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Jose Luis Castro Pineiro; Ian Churcher; Alexander Richard Guiblin; Timothy Harrison; Sonia Kerrard; Andrew Madin; Alan John Nadin; Andrew Pate Owens; Timothy Jason Sparey; Martin Richard Teall; Susannah Williams
- Web page: https://patentgrep.com/patent/US20040082572A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 243/14: 1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D 243/24: Oxygen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 487/04: Ortho-condensed systems
- C07D 491/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel class of 1,4- and 1,5-benzodiazepines of formula (I) is disclosed. The compounds modulate the processing of amyloid precursor protein by γ-secretase, and hence find use in the treatment or prevention of conditions associated with the deposition of β-amyloid, such as Alzheimer's disease. 1

## Claims

### Claim 1

The use, for the manufacture of a medicament for the treatment or prevention of a condition associated with the deposition of β-amyloid, of a compound of formula I:
39
wherein:
n is 0-3;
each Rx independently represents halogen, —CN, —NO2, C1-6alkyl, polyfluoroC1-6alkyl, —OH or C1-4alkoxy;
-A-B-represents:
40
X represents O, S or N—Ra where Ra together with R1 completes a fused imidazole or 4,5-dihydroimidazole ring;
Y represents —CH(Rb)—, —(CH2)x—CH(ORc)—, —CH(CH2OCORb)—, —CH(NHC(O)Rb)—, —(CH2)x—C(O)—, —(CH2)x—C(NORb)—, —CH(OSO2NH2)—, —O— or —S—; where x is 0 or 1, Rb represents H or C1-6alkyl or C2-6alkenyl, either of which is optionally substituted with halogen, CN, NO2, CF3, OH, CO2H, C1-4alkoxy or C1-4alkoxycarbonyl, and Rc represents Rb or tris(C1-6alkyl)silyl;
R1 represents H, C1-6alkyl, C3-8cycloalkyl, C2-6alkenyl, C2-6alkynyl or polyfluoroC1-6alkyl, said alkyl, cycloalkyl, alkenyl and alkynyl groups being optionally substituted by halogen, —CN, —NO2, aryl, heteroaryl, —COR6, —CO2R6, —CON(R6)2, —OCOR7, —NR6COR7, —NR6SO2R7, —SO3R6, —SO2N(R6)2, —OR6, —SR6 or —N(R6)2; or when X is N—Ra, R1 together with Ra completes a fused imidazole or 4,5-dihydroimidazole ring;
R2 represents C1-6alkyl, C3-6cycloalkyl, C2-6alkenyl, C2-6alkynyl, polyfluoroC1-6alkyl, aryl, heteroaryl, —OR7, —Oaryl, —N(R8)2 or —NR6COR9, said alkyl, cycloalkyl, alkenyl and alkynyl groups optionally being substituted by halogen, —CN, —NO2, aryl, heteroaryl, —COR6, —CO2R6, —CON(R6)2, —OCOR7, —NR6COR7, —NR6SO2R7, —SO3R6, —SO2N(R6)2, —OR6, —SR6 or —N(R6)2;
R2a represents H or C1-6alkyl;
or R2 and R2a together complete a C3-6cycloalkyl group;
R3 represents aryl, heteroaryl, C1-6alkyl, polyfluoroC1-6alkyl, C3-8cycloalkyl or C3-8cycloalkylC1-6alkyl;
R4 represents H, halogen, —CN, C1-10alkyl, C3-10cycloalkyl, C2-10alkenyl, C2-10alkynyl, aryl, heteroaryl, —OR8 or —N(R8)2, said alkyl, cycloalkyl, alkenyl and alkynyl groups optionally being substituted by halogen, —CN, —NO2, aryl, heteroaryl, —COR6, —CO2R6, —CON(R6)2, —OCOR7, —NR6COR7, —NR6SO2R7, —SO3R6, —SO2N(R6)2, —OR6, —SR6 or —N(R6)2;
R5 represents H, C1-6alkyl or benzyl which optionally bears up to 3 substituents independently selected from halogen, —CN, —NO2, —OH and methoxy;
each R6 independently represents H, polyfluoroC1-6alkyl, or C1-6alkyl which is optionally substituted with halogen, —CN, —NO2, —OH, —SH, —NH2, phenyl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, C1-4alkoxy, C1-4alkylthio, C1-4alkylamino, di(C1-4alkyl)amino, —CO2H, —CO2C1-4alkyl, —CONH2, —CONHC1-4alkyl or —CON(C1-4alkyl)2; or two R6 groups attached to a single nitrogen atom may complete a heterocyclic ring or condensed ring system of from 3 to 12 members including the said nitrogen, the remaining atoms being selected from C, N, O and S, and the ring or condensed ring system optionally bearing up to 3 substituents independently selected from C1-6alkyl, polyfluoroC1-6alkyl, C2-7acyl, —OH and —CONH2;
R7 represents R6 that is other than H;
R8 represents R6, aryl or heteroaryl;
R9 represents aryl, heteroaryl, C3-6cycloalkyl or —OR7;
“aryl” refers to phenyl which is optionally fused to a 5-7 membered saturated or unsaturated ring which may be carbocyclic or may comprise up to 3 heteroatoms selected from nitrogen, oxygen and sulphur, and which may be oxo-substituted, said phenyl and optional fused ring together bearing 0-3 substituents independently selected from C1-6alkyl [which is optionally substituted with halogen, —CN, —NO2, —OH, —SH, —NH2, C1-4alkoxy, C1-4alkylthio, C1-4alkylamino, di(C1-4alkyl)amino, —CO2H, —CO2C1-4alkyl, —CONH2, —CONHC1-4alkyl or —CON(C1-4alkyl)2], polyfluoroC1-6alkyl, halogen, —CN, —NO2, heteroaryl, —COR6, —CO2R6, —CON(R6)2, —OCOR7, —NR6COR7, —NR6SO2R7, —SO3R6, —SO2N(R6)2, —OR6, —SR6 and —N(R6)2;
“heteroaryl” refers to a heteroaromatic ring of 5 or 6 members, at least one member being nitrogen, oxygen or sulphur and the remainder carbon, said ring optionally being fused to a 5-7 membered saturated or unsaturated ring which may be carbocyclic or may comprise up to 3 heteroatoms selected from nitrogen, oxygen and sulphur, and which may be oxo-substituted, the heteroaromatic ring and optional fused ring together bearing 0-3 substituents independently selected from C1-6alkyl [which is optionally substituted with halogen, —CN, —NO2, —OH, —SH, —NH2, C1-4alkoxy, C1-4alkylthio, C1-4alkylamino, di(C1-4alkyl)amino, —CO2H, —CO2C1-4alkyl, —CONH2, —CONHC1-4alkyl or —CON(C1-4alkyl)2], polyfluoroC1-6alkyl, halogen, —CN, —NO2, phenyl, —COR6, —CO2R6, —CON(R6)2, —OCOR7, —NR6COR7, —NR6SO2R7, —SO3R6, —SO2N(R6)2, —OR6, —SR6 and —N(R6)2;
with the proviso that when Y represents —CH(ORc)—, —C(O)— or —C(NORb)—, R3 represents aryl or heteroaryl;
or a pharmaceutically acceptable salt thereof

### Claim 2 (depends on 1)

A compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, with the further proviso that when n is 0, and X represents O, and R1 represents H or methyl, and R2a represents H, and R3 represents phenyl, and A-B represents —C(R4)═N— where R4 represents phenyl, R2 does not represent amino or t-butoxycarbonylamino.

### Claim 3 (depends on 2)

A compound according to claim 2 of formula II:
41
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

A compound according to claim 3 of formula IIa:
42
wherein:
Ry, Rz, Rv and Rw are independently H, CF3 or halogen;
Yl is —CH(Rb)—, —CH(ORc)—, —CH(CH2OCORb)—, —CH(NHC(O)Rb)—, —C(O)—, —C(NORb)— or —O—;
R1a is H, polyfluoroC1-4alkyl, or C1-4alkyl which is optionally substituted by —OH, —CN, halogen, aryl, heteroaryl, carbamoyl, N-(C1-4alkyl)carbamoyl, N,N-di(C1-4alkyl)carbamoyl or dimethylamino;
R2b is selected from C1-6alkyl, C3-6cycloalkyl, polyfluoroC1-6alkyl, (R6a)2N—C1-6alkyl, C2-6alkenyl, heteroaryl, C1-6alkoxy, —N(R6a)2, —NHCO2R7a, and phenyl which is optionally substituted by halogen;
R4a is selected from C1-10alkyl, C3-10cycloalkyl, —N(R6a)2, pyridyl which is optionally substituted by methoxy; or phenyl which is optionally substituted by up to 2 groups selected from halogen, methoxy, CF3, OCF3 and carbamoyl or which is fused to a heterocyclic ring or to an oxo-substituted carbocyclic ring;
each R6a independently represents H or C1-6alkyl which is optionally substituted with —CONH2, or two R6a groups together with a nitrogen atom to which they are commonly attached complete a heterocyclic ring or condensed ring system of 3-12 members including the said nitrogen, the remaining atoms being selected from C, O, N and S, and the ring or condensed ring system optionally bearing up to 3 substituents selected from C1-6, polyfluoroC1-6alkyl, —OH, and —CONH2; and
R7a represents t-butyl or benzyl;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 2)

A compound according to claim 2 of formula IIc:
43
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 4, 5)

A compound according to claim 5 of formula IId:
44
where Rv, Rz, Rv, Rw, Y1, R1a and R2b are as defined in claim 4;
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 4, 6)

A compound according to claim 4 or claim 6 wherein Y1 is —CH2—, —CH(OH)—, —O—, —CH(CH2OH)—, —CH(CH2OCOCH2CH2CO2H)—, —CH(OCH3)—, —CH(CH═CH2)—, —CH(CH2Br)— or —C(═NOH)—.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

A pharmaceutical composition comprising one or more compounds according to any of claims 2-7, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7)

A compound according to any of claims 2-7 for use in treatment of the human or animal body.

### Claim 10 (depends on 1)

A method of treatment of a subject suffering from or prone to Alzheimer's disease which comprises administering to that subject an effective amount of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof.
